Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, PhD, the company’s Chief Scientific Officer, will present data from preclinical and clinical studies related to DARE-BV1 at the 2021 Controlled Release Society (CRS) Virtual Annual Meeting on July 27th. Daré submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for DARE-BV1 for the treatment of bacterial vaginosis in June of 2021.
- DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
- Find out more information about the 2021 CRS Virtual Annual Meeting by visiting the CRS website: https://www.controlledreleasesociety.org/events/2021-crs-virtual-annual-... .
- Dr. Friends presentation will be available following the conclusion of the 2021 CRS Virtual Annual Meeting under Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com .
- Dar cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.